In HER2-positive breast cancer patients with brain metastases treated with trastuzumab and capecitabine, tucatinib increased median overall survival from 12 months to 18.1 months in a phase 2 trial.
Medscape Medical News …read more
Miami OBGYN Society
A Membership Organization of South Florida Obstetrician-Gynecologists
